Evidence map›Paper›PMID 41284009›Full record

ArticlePediatric nephrology (Berlin, Germany)2026

Belimumab combined with mycophenolate mofetil in a child with frequently relapsing, steroid-dependent nephrotic syndrome.

Yi Mao, Jia He, Weijie Kang, Jialu Lu, Lei Yin, Youying Mao

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi MaoDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Pudong District, Shanghai, 200127, China.
Jia HeDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Pudong District, Shanghai, 200127, China.
Weijie KangDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Pudong District, Shanghai, 200127, China.
Jialu LuDepartment of Pediatrics, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 201600, China.
Lei YinDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Pudong District, Shanghai, 200127, China.
Youying MaoDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Pudong District, Shanghai, 200127, China. maoyouying2012@163.com.ORCID http://orcid.org/0000-0002-7598-7386

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frequently relapsing, steroid-dependent nephrotic syndrome (FRNS/SDNS) remains a therapeutic challenge. Rituximab, a B-cell-depleting agent, is effective and widely used for FRNS/SDNS, but its use can be limited by rare, serious adverse effects. Belimumab, a monoclonal antibody targeting B-cell activating factor (BAFF), is approved for treating adult systemic lupus erythematosus (SLE) and lupus nephritis (LN). We report a pediatric case of FRNS/SDNS refractory to conventional immunosuppressive regimens and intolerant of rituximab due to serious complications, who subsequently maintained complete remission for nearly one year after steroid withdrawal while receiving belimumab added to ongoing mycophenolate mofetil (MMF). This case suggests that belimumab combined with MMF is effective for refractory NS. However, as a single case report, its efficacy requires further strengthening through more cases.

Indexed as

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsMycophenolic AcidNephrotic SyndromeChildDrug Therapy, CombinationFemaleHumansMaleRecurrenceRemission InductionTreatment OutcomeAntibodies, Monoclonal, HumanizedbelimumabImmunosuppressive AgentsMycophenolic AcidB-cell activating factorBelimumabCase reportNephrotic syndrome

Identifiers

PMID41284009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.